Zymeworks 8-K: Executive/Director Changes or Compensation Update
Ticker: ZYME · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1937653
Complexity: simple
Sentiment: neutral
Topics: executive-change, compensation, corporate-governance
TL;DR
**Zymeworks filed an 8-K on Jan 5, indicating executive changes or compensation updates on Jan 3.**
AI Summary
Zymeworks Inc. filed an 8-K on January 5, 2024, reporting an event that occurred on January 3, 2024. This filing indicates a change in the company's executive or director compensation arrangements, or a departure/election of officers, as per Item 5.02. While specific names or dollar amounts are not detailed in this summary, the filing signals potential shifts in leadership or executive incentives. For investors, this matters because changes in executive compensation or leadership can impact company strategy, performance, and ultimately, stock value.
Why It Matters
Changes in executive leadership or compensation can signal strategic shifts or financial health, directly influencing investor confidence and the company's future direction.
Risk Assessment
Risk Level: medium — The filing indicates changes in leadership or compensation, which can introduce uncertainty regarding future company direction and stability.
Analyst Insight
Investors should monitor Zymeworks Inc.'s subsequent announcements or filings for specific details regarding the executive changes or compensation arrangements, as these could impact future company strategy and performance. This filing is a notification of an event, not the event itself.
Key Numbers
- 001-41535 — Commission File Number (identifies Zymeworks Inc. with the SEC)
- 1934 Act — SEC Act (under which the 8-K was filed)
- 13 — Section of Exchange Act (pursuant to which the report was filed)
- 15(d) — Section of Exchange Act (pursuant to which the report was filed)
Key Players & Entities
- Zymeworks Inc. (company) — registrant filing the 8-K
- January 3, 2024 (date) — date of the earliest event reported
- January 5, 2024 (date) — date the 8-K was filed
- Delaware (company) — state of incorporation for Zymeworks Inc.
- ZYME (company) — trading symbol for Zymeworks Inc.
- The Nasdaq Stock Market LLC (company) — exchange where Zymeworks Inc. common stock is registered
Forward-Looking Statements
- Zymeworks Inc. will provide more specific details regarding the executive changes or compensation arrangements in a subsequent filing or announcement. (Zymeworks Inc.) — medium confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 3, 2024.
What items of information are included in this 8-K filing for Zymeworks Inc.?
This 8-K filing includes Item 5.02, 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers,' and Item 9.01, 'Financial Statements and Exhibits.'
What is the trading symbol and the exchange where Zymeworks Inc.'s common stock is registered?
Zymeworks Inc.'s common stock trades under the symbol ZYME and is registered on The Nasdaq Stock Market LLC.
What is Zymeworks Inc.'s state of incorporation and business address?
Zymeworks Inc. is incorporated in Delaware, and its business address is 108 Patriot Drive, Suite A, Middletown, Delaware, 19709.
When was this 8-K filing filed with the SEC?
This 8-K filing was filed with the SEC on January 5, 2024.
Filing Stats: 633 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-01-05 07:00:34
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
Filing Documents
- d657602d8k.htm (8-K) — 27KB
- d657602dex101.htm (EX-10.1) — 13KB
- 0001193125-24-002851.txt ( ) — 163KB
- zyme-20240103.xsd (EX-101.SCH) — 3KB
- zyme-20240103_lab.xml (EX-101.LAB) — 18KB
- zyme-20240103_pre.xml (EX-101.PRE) — 11KB
- d657602d8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 3, 2024, Zymeworks BC Inc. ("Zymeworks BC"), a subsidiary of Zymeworks Inc. (the "Company"), entered into a second amendment to the Employment Agreement effective January 15, 2022, as amended on December 30, 2022 (as amended, the "Employment Agreement"), between Mr. Kenneth Galbraith, the Company's Chair, Chief Executive Officer and President, and Zymeworks BC (the "Amendment"). The Amendment amends the Employment Agreement to (a) establish Mr. Galbraith's principal place of employment as the United Kingdom, or another location as agreed upon between the parties, which removes the requirement for Mr. Galbraith to relocate to Vancouver, B.C. or Seattle, Washington, (b) provide that the Company will continue to reimburse or pay travel and lodging expenses for Mr. Galbraith and his immediate family for one trip per calendar year to Vancouver, BC or Seattle, WA, (c) provide that the Company will continue to secure and directly pay rental costs associated with temporary housing for Mr. Galbraith in Vancouver, BC and (d) make certain other administrative and conforming changes. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment #2 to Employment Agreement, dated as of January 3, 2024, by and among Kenneth Galbraith and Zymeworks BC Inc. 104 Cover Page Interactive Data File (embedded as Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ZYMEWORKS INC. (Registrant) Date: January 5, 2024 By: /s/ Chris Astle Name: Title: Chris Astle Senior Vice President and Chief Financial Officer 3